RB1 and cervical cancer: A caveat of our present study was that we were unable to assess palbociclib sensitivity using HPVU cervical cancer cell lines due to the C33A and HT3 cell lines harboring RB1 mutations [24], and palbocilib sensitivity has been previously reported to be dependent on intact RB1 signaling.